Browse studies

Find your next paid study

68 recruiting studies matching your filters

GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Homologous Recombinant Deficient (HRD +) Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Da…

Stage III Ovarian CancerStage IV Ovarian CancerStage III Primary Peritoneal Cancer+3 more

Estimated

~$10 – $6,250

GOG FoundationNCT05659381

Observational

Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on phy…

Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+10 more

Estimated

~$10 – $7,500

Roswell Park Cancer Institute

Phase 1

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety a…

Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms+3 more

Estimated

~$10 – $8,750

Bio-Path Holdings, Inc.NCT04196257

Phase 2

A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a s…

Ovarian CancerFallopian Tube CarcinomaOvarian Carcinoma+7 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06290193

Phase 2

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Epithelial Ovarian CancerPrimary PeritonealFallopian Tube Cancer+1 more

Estimated

~$10 – $8,750

TORL Biotherapeutics, LLCNCT06690775

Phase 1

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynami…

Solid TumorEpithelial Ovarian CancerFallopian Tube Cancer+1 more

Estimated

~$10 – $8,750

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04516447

Phase 1

Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian Cancer

This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a peri…

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+13 more

Estimated

~$10 – $6,250

Phase 2

A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with cle…

Ovary CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06617923